AimTo quantify the year-to-year variability of altitude-induced changes in haemoglobin mass (Hbmass) in elite team-sport athletes.Methods12 Australian-Footballers completed a 19-day (ALT1) and 18-day (ALT2) moderate altitude (∼2100 m), training camp separated by 12 months. An additional 20 participants completed only one of the two training camps (ALT1 additional n=9, ALT2 additional n=11). Total Hbmass was assessed using carbon monoxide rebreathing before (PRE), after (POST1) and 4 weeks after each camp. The typical error of Hbmass for the pooled data of all 32 participants was 2.6%. A contemporary statistics analysis was used with the smallest worthwhile change set to 2% for Hbmass.ResultsPOST1 Hbmass was very likely increased in ALT1 (3.6±1.6%, n=19; mean±∼90 CL) as well as ALT2 (4.4±1.3%, n=23) with an individual responsiveness of 1.3% and 2.2%, respectively. There was a small correlation between ALT1 and ALT2 (R=0.21, p=0.59) for a change in Hbmass, but a moderately inverse relationship between the change in Hbmass and initial relative Hbmass (g/kg (R=−0.51, p=0.04)).ConclusionsTwo preseason moderate altitude camps 1 year apart yielded a similar (4%) mean increase in Hbmass of elite footballers, with an individual responsiveness of approximately half the group mean effect, indicating that most players gained benefit. Nevertheless, the same individuals generally did not change their Hbmass consistently from year to year. Thus, a ‘responder’ or ‘non-responder’ to altitude for Hbmass does not appear to be a fixed trait.

Aim: The use of external and internal load is an important aspect of monitoring systems in team sport. The aim of this study was to validate a novel measure of training load by quantifying the training-performance relationship of elite Australian footballers.Methods: The primary training measure of each of 36 players was weekly load derived from a weighted combination of Global Positioning System (GPS) data and perceived wellness over a 24-week season. Smoothed loads representing an exponentially weighted rolling average were derived with decay time constants of 1.5, 2, 3, and 4 weeks. Differential loads representing rate of change in load were generated in similar fashion. Other derived measures of training included monotony, strain and acute:chronic ratio. Performance was a proprietary score derived from match performance indicators. Effects of a 1 SD within-player change below and above the mean of each training measure were quantified with a quadratic mixed model for each position (defenders, forwards, midfielders, and rucks). Effects were interpreted using standardization and magnitude-based inferences.Results: Performance was generally highest near the mean or ~1 SD below the mean of each training measure, and 1 SD increases in the following measures produced small impairments: weekly load (defenders, forwards, and midfielders); 1.5-week smoothed load (midfielders); 4-week differential load (defenders, forwards, and midfielders); and acute:chronic ratio (defenders and forwards). Effects of other measures in other positions were either trivial or unclear.Conclusion: The innovative combination of load was sensitive to performance in this elite Australian football cohort. Periods of high acute load and sustained increases in load impaired match performance. Positional differences should be taken into account for individual training prescription.

Successful management of epithelial skin cancers with imiquimod 5% cream (Aldara®), an immunomodulatory agent, led to speculation that it may promote an immune response against melanoma. Studies, mostly case reports, have assessed the value of imiquimod as a topical treatment for dermal melanoma metastases that prove difficult to manage surgically. The precise value of imiquimod, however, in treatment of dermal and subcutaneous metastases remains unclear. A case at our institution elucidates histopathologically that subcutaneous metastases may progress despite excellent treatment of superficial dermis in the same location. In preparation for a clinical trial using imiquimod to treat patients with dermal melanoma metastases, we have treated several patients off protocol. We present a case report in which the observed changes are documented photographically and histologically. The patient experienced dramatic improvement in the locally treated dermis with concurrent regional treatment failure in the subcutaneous space. Our experience supports growing evidence that imiquimod for some provides an effective option for dermal disease. The unique histological documentation we provide regarding the differential effectiveness of imiquimod in treating various tissue components may help guide future investigations regarding optimal clinical application of imiquimod therapy for melanoma metastases.

Purpose:Little research has been done on the physiological and performance effects of altitude training on team-sport athletes. Therefore, this study examined changes in 2000-m time-trial running performance (TT), hemoglobin mass (Hbmass), and intramuscular carnosine content of elite Australian Football (AF) players after a preseason altitude camp.Methods:Thirty elite AF players completed 19 days of living and training at either moderate altitude (~2130 m; ALT, n = 21) or sea level (CON, n = 9). TT performance and Hbmass were assessed preintervention (PRE) and postintervention (POST1) in both groups and at 4 wk after returning to sea level (POST2) in ALT only.Results:Improvement in TT performance after altitude was likely 1.5% (± 4.8–90%CL) greater in ALT than in CON, with an individual responsiveness of 0.8%. Improvements in TT were maintained at POST2 in ALT. Hbmass after altitude was very likely increased in ALT compared with CON (2.8% ± 3.5%), with an individual responsiveness of 1.3%. Hbmass returned to baseline at POST2. Intramuscular carnosine did not change in either gastrocnemius or soleus from PRE to POST1.Conclusions:A preseason altitude camp improved TT performance and Hbmass in elite AF players to a magnitude similar to that demonstrated by elite endurance athletes undertaking altitude training. The individual responsiveness of both TT and Hbmass was approximately half the group mean effect, indicating that most players gained benefit. The maintenance of running performance for 4 wk, despite Hbmass returning to baseline, suggests that altitude training is a valuable preparation for AF players leading into the competitive season.

Intravenous immunoglobulin (IVIG) provides replacement therapy in immunodeficiency and immunomodulatory therapy in inflammatory and autoimmune diseases. This paper describes the immune mechanisms underlying six major non-primary immunodeficiency pediatric diseases and the diverse immunomodulatory functions of IVIG therapy. In Kawasaki disease, IVIG plays a major, proven, and effective role in decreasing aneurysm formation, which represents an aberrant inflammatory response to an infectious trigger in a genetically predisposed individual. In immune thrombocytopenia, IVIG targets the underlying increased platelet destruction and decreased platelet production. Although theoretically promising, IVIG shows no clear clinical benefit in the prophylaxis and treatment of neonatal sepsis. Limitations in research design combined with the unique neonatal immunologic environment offer explanations for this finding. Inflammation from aberrant immune activation underlies the myelinotoxic effects of Guillain-Barré syndrome. HIV-1 exerts a broad range of immunologic effects and was found to decrease serious bacterial infections in the pre-highly active anti-retroviral therapy (HAART) era, although its practical relevance in the post-HAART era has waned. Clinical and experimental data support the role of immune mechanisms in the pathogenesis of childhood epilepsy. IVIG exerts anti-epileptic effects through targeting upregulated cytokine pathways and antibodies thought to contribute to epilepsy. Applications in six additional pediatric diseases including pediatric asthma, atopic dermatitis, cystic fibrosis, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS), autism, and transplantation will also be briefly reviewed. From autoimmunity to immunodeficiency, a dynamic immunologic basis underlies major pediatric diseases and highlights the broad potential of IVIG therapy.